Further studies on the specificity of anti-human B cell monoclonal antibodies (BR3, BR31)--reactivity with hematopoietic malignant cells.
We present results concerning the reactivity of two moAbs (BR3, BR31) with human B cell lines and malignant B cells from patients. The first antibody BR3 shows a broad reactivity with B cell malignancies and B cell lines. It also weakly stains some non-T ALL cells and is negative on plasma cell tumors. The second moAb BR31 shows a restricted reactivity. It stains only HCL and PLL cells as well as Burkitt's lymphoma lines. Some moderate staining was also observed on 4 out of 12 cases of CLL and some non-Hodgkin lymphomas. PLL cells, cultured with polyclonal activators, lose BR31 Ag by day 4 of culture. These results suggest that BR3 Ag is present on the cell surface throughout B cell ontogeny while BR31 Ag expression is related to a particular stage of B cell maturation.
Skibiński
G
G
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław.
Klimczak
A
A
Wieczorek
Z
Z
D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000944:Antigens, Differentiation, B-Lymphocyte; D001402:B-Lymphocytes / Q000166:cytology / Q000276:immunology*; D002454:Cell Differentiation; D002460:Cell Line; D006801:Humans; D014407:Tumor Cells, Cultured / Q000276:immunology
D000911:Antibodies, Monoclonal; D000944:Antigens, Differentiation, B-Lymphocyte